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OBJECTIVE—Caloric restriction (CR) has been shown to re-
tard aging processes, extend maximal life span, and consistently
increase insulin action in experimental animals. The mechanism
by which CR enhances insulin action, speciﬁcally in higher
species, is not precisely known. We sought to examine insulin
receptor signaling and transcriptional alterations in skeletal
muscle of nonhuman primates subjected to CR over a 4-year
period.
RESEARCH DESIGN AND METHODS—At baseline, 32 male
adult cynomolgus monkeys (Macaca fascicularis) were random-
ized to an ad libitum (AL) diet or to 30% CR. Dietary intake, body
weight, and insulin sensitivity were obtained at routine intervals
over 4 years. At the end of the study, hyperinsulinemic-euglyce-
mic clamps were performed and skeletal muscle (vastus latera-
lis) was obtained in the basal and insulin-stimulated states for
insulin receptor signaling and gene expression proﬁling.
RESULTS—CR signiﬁcantly increased whole-body insulin–me-
diated glucose disposal compared with AL diet and increased
insulin receptor signaling, i.e., insulin receptor substrate (IRS)-1,
insulin receptor phosphorylation, and IRS–associated PI 3-kinase
activity in skeletal muscle (P  0.01, P  0.01, and P  0.01,
respectively). Gene expression for insulin signaling proteins, i.e.,
IRS-1 and IRS-2, were not increased with CR, although a signif-
icant increase in protein abundance was noted. Components of
the ubiquitin-proteasome system, i.e., 20S and 19S proteasome
subunit abundance and 20S proteasome activity, were signiﬁ-
cantly decreased by CR.
CONCLUSIONS—CR increases insulin sensitivity on a whole-
body level and enhances insulin receptor signaling in this higher
species. CR in cynomolgus monkeys may alter insulin signaling
in vivo by modulating protein content of insulin receptor signal-
ing proteins. Diabetes 58:1488–1498, 2009
C
aloric restriction (CR) can dramatically extend
life span in lower species by retarding aging
processes and reducing the incidence and se-
verity of age-related diseases whether initiated
in young or old age in mammalian models (1–5). Although
longevity studies have not been completed in humans, it is
well documented that lifestyle modiﬁcation that includes
CR can signiﬁcantly delay progression and onset of type 2
diabetes. However, the cellular mechanism(s) by which
CR exerts its effects on longevity and attenuates progres-
sion to metabolic diseases is not precisely known. CR has
been postulated to reduce protein glycation and glyco-
oxidation, scavenge reactive oxygen species, modulate
thermogenesis, assist in DNA repair, and alter oncogene
expression and protein degradation (5–10). Recently, sir-
tuin 1 (SIRT1) (one of the human homologues of the
budding yeast Sir2) has been attracting great interest
because of its role in the antiaging effects of CR (11,12).
With speciﬁc regard to the mechanism of action, study-
ing the effects of CR on aging processes and age-related
diseases in a long-lived nonhuman primate, particularly as
it relates to the analysis of the genome, could provide
greater insights into mechanisms of aging and effects on
aging in humans. Although human studies have only
recently been reported (13), there has been intense study
of the metabolic effects of CR in higher species for many
years. Speciﬁcally, we demonstrated that CR improved
insulin sensitivity and reduced intra-abdominal fat with
aging in a 4-year study in cynomolgus monkeys (14). An
improvement in insulin sensitivity appears to be one of the
most consistent features of CR, as observed in both rodent
and nonhuman primate models (1–3,14–18). However, the
cellular mechanism by which CR speciﬁcally enhances
insulin action is not precisely known.
To evaluate the potential mechanism by which CR
enhances insulin action would require investigation at
multiple tissues in vivo because coordinated mechanisms
from liver, adipocytes, and skeletal muscle all contribute
to whole-body insulin action. Yet, analysis of skeletal
muscle transcriptional regulation with CR would be an
important step given that skeletal muscle is the major site
of insulin-mediated glucose disposal. In addition, a major
metabolic effect reported for insulin in muscle is inhibition
of protein degradation, mediated by the ubiquitin-protea-
some system (19,20). Interestingly, insulin resistance was
also reported to accelerate proteasome-dependent degra-
dation of muscle proteins (21), indicating that insulin
signaling exerts control over proteasome function in skel-
etal muscle. Thus, we sought to determine a potential
mechanism by which CR enhances insulin action in a
higher species by evaluating insulin signaling and gene
expression in skeletal muscle in a nonhuman primate
subjected to chronic CR.
RESEARCH DESIGN AND METHODS
The effect of chronic CR to modulate cellular insulin signaling and transcrip-
tional regulation was assessed in skeletal muscle obtained from nonhuman
primates subjected to a 4-year period of 30% CR compared with ad libitum
(AL) feeding conditions. The metabolic and physiological changes observed in
this cohort with CR were previously reported (14). Speciﬁcally, 32 feral adult
male cynomolgus monkeys (Macaca fascicularis) (mean  SEM age 8.2  1.2
years) were part of a randomized trial in which the independent effect of CR
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and composition were evaluated (Fig. 1).
The animals were acquired directly from the Institute Pertanian (Bogar,
Indonesia) and quarantined for 3 months. Animals were housed socially in
pairs except when separated at mealtime by sliding a partition to separate
them (14). Beginning in the 4th month and throughout the pretrial (months
4–6), all animals were fed a moderately atherogenic diet (0.25 mg cholesterol/
calorie) containing 30% of calories from fat. Caloric intake for each animal
was assessed by feeding a known allotment and weighing the uneaten food
(14). After pretrial evaluations, the animals were assigned to AL or CR diet
groups using a stratiﬁed randomization. The CR diet was introduced over a
3-month transition period (90% of AL intake during the 1st month, 80% during
the 2nd month, and 70% during the 3rd month and thereafter). Additional
vitamin and mineral mixture, -sitosterol, and crystalline cholesterol were
added to the CR diet so that the same amount of these components was
ingested regardless of the randomized group (14).
Insulin sensitivity. Insulin sensitivity was assessed at 6-month intervals
using a modiﬁed minimal model and at the end of the study using a
hyperinsulinemic-euglycemic clamp as described (14). At the baseline of the
clamp, a biopsy of the vastus lateralis muscle was obtained. After the insulin
infusion, repeat biopsies were obtained at 5, 20, and 40 min of the clamp.
Muscle samples (200 mg wet wt) were immediately placed into liquid
nitrogen and then stored at 80°C. There was no difference between the
steady state plasma glucose (5.38  0.10 vs. 5.42  0.10 mmol/l) or plasma
insulin levels observed during the clamp (1,472  145 vs. 1,535  155 pmol/l)
for either the CR or AL groups, respectively.
Tissue preparation. Muscle tissue lysates were prepared by dissection and
homogenized in buffer A (25 mmol/l HEPES, pH 7.4, 1% Nonidet P-40, 137
mmol/l NaCl, 1 mmol/l phenylmethylsulfonyl ﬂuoride, 10 g/ml aprotinin, 1
g/ml pepstatin, and 5 g/ml leupeptin), using a PRO 200 homogenizer (PRO
Scientiﬁc, Oxford, CT). The samples were centrifuged at 14,000g for 20 min at
4°C, and protein content of the supernatant was determined (Bio-Rad protein
assay kit; Bio-Rad Laboratories, Hercules, CA). Supernatants (50 g) were
resolved by SDS-PAGE and subjected to immunoblotting using chemilumines-
cence reagent (PerkinElmer Life Science, Boston, MA) and quantiﬁed as
described (22). The 19S proteasome base anti-S5A/Rpn10 antibodies were
ordered from Calbiochem (Gibbstown, NJ). Antibodies for phospho–insulin
receptor substrate (IRS)-1 (Tyr612), phospho–insulin receptor (IR) (Tyr1150/
1151), phosphoinositol (PI) 3-kinase protein 85 (p85 of PI 3-kinase), phospho-
Akt (Ser473), IRS-1 and IRS-2, 20S proteasome subunit 2i, Akt, serum- and
glucocorticoid-inducible kinase 1 (SGK1), signal transducer and activator of
transcription 3 (STAT3), and SIRT1 antibodies were obtained from Upstate
Biotech (Lake Placid, NY). Anti-19S proteasome lid subunits S9/Rpn6 and
S14/Rpn12 antibodies were ordered from BIOMOL International (Plymouth
Meeting, PA). GLUT4 monoclonal antibody was obtained from R&D Systems
(Minneapolis, MN). Lipoprotein lipase (LPL) antibody was purchased from
GeneTex (San Antonio, TX) and -actin from Afﬁnity Bioreagents (Golden,
CO). IR -subunit was obtained from Santa Cruz Biotechnology (Santa Cruz,
CA).
IR tyrosine kinase activity. IR tyrosine kinase activity was assessed as
described by Le Marchand-Brustel et al. (23) with modiﬁcation. Brieﬂy, 500 g
of muscle lysate at each time point was added to 50 l of agarose bound wheat
germ agglutinin incubated at room temperature for 2 h. After washing with
buffer A, bound receptor was eluted by 3 mol/l N-acetyl-D-glucosamine
solution. IR kinase activity was initialed by adding 40 l of reaction solution
consisting of 1 mmol/l DTT, 10 mmol/l MgCl2, 3 mmol/l MnCl2, and 5 mol/l
[r-
32P]ATP. Reactions were carried out for 30 min at 22°C and terminated by
adding 2 l of 0.5 mol/l EDTA and 10 lo f5 0 0mol/l ATP. Then 2 go fI R
-subunit antibody and 50 l of protein A agarose beads were added to the
reaction mixture and incubated at room temperature for 30 min. After
extensive washing with buffer A, 40 l of electrophoresis sample buffer was
added and heated at 95°C for 4 min. Following SDS-PAGE, gels were dried and
bands visualized by autoradiography.
IR -subunit tyrosine phosphorylation. IR -subunit tyrosine phosphory-
lation and IR -subunit abundance were measured by Western blot techniques
(24,25). Brieﬂy, 50 g of lysates prepared as described above was subjected to
8% SDS-PAGE and transferred to nitrocellulose membrane. IR -subunit
phosphorylation was detected with anti–phospho-IR (Tyr1150/1151) antibody.
The membrane was striped with strip buffer and reprobed with anti–IR
-subunit and -actin antibodies, respectively.
Insulin-stimulated tyrosine phosphorylation of IRS-1, PI 3-kinase ac-
tivity, and Akt phosphorylation. To assess IRS-1 phosphorylation, muscle
lysates were subjected to SDS-PAGE (24). The bands were detected with
anti–phospho-IRS-1 (Tyr612) antibody (26). After measuring phospho-IRS-1
abundance, the membrane was striped with strip buffer and reprobed
with anti–total IRS-1 antibody to obtain abundance. IRS-1–associated PI
3-kinase activities of the muscle at each time point were assessed (25–27). We
conﬁrm that wortmannin treatment could completely inhibit IRS-1–associated
PI 3-kinase activity of muscle tissues (data not shown). Total Akt and pAkt
(Ser473) at each time point were similarly assessed with Western blot
techniques.
Protein content for IRS-2, GLUT4, PI 3-kinase (p85), LPL, SGK1, SIRT1, and
STAT3 in the lysates was measured also using Western blot analysis. Results
of scanning for each gel were normalized by -actin, and the data are
presented as mean  SEM of fold change in CR versus AL.
RNA extraction. Total RNA was extracted from muscle obtained for
microarray and real-time quantitative PCR (qPCR) assays. Frozen tissues were
placed in a mortar in liquid nitrogen, and the tissue was pulverized into
powder using a pestle on dry ice. Total RNA was isolated from the tissue
powder using TRIZOL reagent (Invitrogen, Carlsbad, CA). After DNase I
(Invitrogen) digestion, RNA was further puriﬁed with an RNeasy Mini Kit
(QIAGEN, Germantown, MD). RNA concentration and quality were measured
by an RNA 6000 Nano LabChip kit (Agilent Technologies, Santa Clara, CA).
Gene expression. The Applied Biosystems human genome survey microar-
ray version 2.0 chip containing 32,878 oligonucleotide probes (60-mer) repre-
senting 29,098 individual human genes and more than 1,000 control probes
was used for microarray proﬁling for 10 animals, 5 randomly chosen from
each group. It has been demonstrated that human sequence–based DNA
arrays can be used effectively to detect differential gene expression in a
nonhuman primate (28). Digoxigenin-UTP–labeled cRNA was generated and
linearly ampliﬁed from 1 g of total RNA from each sample using an Applied
Biosystems Chemiluminescent RT-IVT labeling kit according to the manufac-
turer’s protocol. After cRNA was fragmented by heating at 60°C for 30 min, 10
g of cRNA fragments were hybridized at 55°C for 16 h. Chemiluminescence
detection, image acquisition, and analysis were performed according to the
manufacturer’s protocol (Applied Biosystems, Foster, CA). Signals were
quantiﬁed and corrected for background, and ﬁnal images and feature data
were processed by Applied Biosystems 1700 Chemiluminescent Microarray
Analyzer software version 1.1.
Real-time qPCR. The primer sequences of candidate genes were designed
using Primer Express software version 3.0 (Applied Biosystems). A 1-g
aliquot of total RNA for each sample was reverse transcribed in a 100-l
reaction volume with a commercial High-Capacity cDNA Archive Kit (Applied
Biosystems) according to the manufacturer’s protocol. The qPCR was con-
ducted in 384-well microtiter plates on the ABI Prism Sequence Detector 7900
(Applied Biosystems) with Bio-Rad iTaqTM SYBR Green Supermix with ROX
Kits. For each sample of each gene, PCR ampliﬁcation was performed in
triplicate with -actin used as an endogenous control. The mRNA content of
each candidate gene was determined simultaneously in 10 paired (CR and AL)
6 months 48 months 6 months
PRETRIAL                                         TRIAL DETERMINATIONS  EVALUATIONS
32
Non-human
Primates
Pretrial
Determinations Randomize
30% CR
Control (AL)
Necropsy Endpoint
FIG. 1. Demonstration of the study design for the 4-year caloric restriction trial. As shown, after pretrial evaluations, the animals were randomly
assigned to AL or CR diet (30%). After 48 months of intervention, clinical and cellular mechanisms were assessed.
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duplicate.
20S proteasome activity assay. 20S proteasome activity in muscle lysates
obtained in the basal state was measured in duplicate using a 20S Proteasome
Activity Assay Kit (Chemicon International, Temecula, CA). 20S proteasome
chymotrypsin activity was measured by incubating 20 g of each lysate with
ﬂuorophore 7-amino-4-methylcoumarin (AMC)-labeled peptide substrate
LLVY-AMC at 37°C for 60 min. The free AMC released by proteasome activity
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FIG. 2. Caloric intake (A) and body weight (B) for both treatment groups over 4 years of observations are demonstrated. C demonstrates re-
sults of insulin sensitivity assessed every 6 months over the course of study, using the minimal model technique. D demonstrates insulin
sensitivity assessed by hyperinsulinemic-euglycemic clamps conducted at the end of the study. Data are means  SEM (n  16 per group).
SI units  10
4  min
1  U
1  ml. *P < 0.05, **P < 0.01, and ***P < 0.001 for CR versus AL. (All data presented in this ﬁgure have been previously
published, and the ﬁgure was modiﬁed from Cefalu et al. [14] with permission.)
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Winooski, VT). The AMC standard curve was generated with a series dilution
of AMC standard solution. Proteasome activity was conﬁrmed using puriﬁed
20S proteasome as the positive control and is reported as mol/l AMC per mg
protein per h. Each sample/substrate combination was measured both in the
presence and in the absence of MG132 (10 mol/l) or epoxomicin (1 mol/l),
a highly speciﬁc 20S proteasome inhibitor (Boston Biochem, Cambridge, MA)
(29), to account for any nonproteasomal degradation of the substrate.
Statistical analysis. The effects of CR on the trial evaluations measured at
the speciﬁed intervals postrandomization were estimated using repeated-
measures ANCOVA. Analysis of group differences was adjusted for the
prerandomization levels of the outcome measure tested in order to reduce the
variance explained by prerandomization predictors. All tests of hypotheses
and reported P values were two-sided. Whenever a baseline value was used as
a covariate in an ANCOVA model, an interaction term between the group and
the covariate was initially included to check the parallelism assumption. If the
interaction was not signiﬁcant at the 0.10 level of signiﬁcance, and it was
always the case, the interaction term was omitted.
For gene expression, within-array normalization was done with the scan-
ning software from Applied Biosystems based on housekeeping genes on each
array. Global normalization among arrays was accomplished using quantile
normalization (30). ANOVA analysis with Bonferroni adjustment was used for
detecting signiﬁcantly differentiated genes. Differentially expressed genes
between the CR and AL groups were determined based on the following
criteria: Bonferroni-adjusted P  0.05 and fold change in the CR over the AL
group of 1.5. All data analyses were carried out using SAS (Cary, NC). Public
databases including David/Ease, GenMAPP, Panther, GOTM, and TreeView
version 1.6 were used to assess functional gene cluster analysis (31).
RESULTS
The clinical, phenotypic, and metabolic effects of CR for
the cohort of cynomolgus monkeys (Macaca fascicularis)
evaluated were previously reported in detail (14). Com-
pared with the AL group, animals randomized to CR were
observed to have signiﬁcantly reduced dietary intake,
reduced body weight, increased insulin sensitivity, and
reduced intra-abdominal fat with aging (Fig. 2A–D) (14).
The effect of CR was noted during the 1st year of obser-
vation and maintained over the 4 years of observation, as
demonstrated not only from periodic assessment of insulin
sensitivity with the minimal model (Fig. 2C), but also from
the assessment with hyperinsulinemic-euglycemic clamps
obtained at study end (Fig. 2D) (14).
Insulin signaling. Animals randomized to CR had signif-
icantly increased skeletal muscle protein abundance of
IRS-1, IRS-2, IR -subunit, PI 3-kinase (p85), and GLUT4
compared with that in the AL group (Fig. 3). When
compared with AL animals, animals randomized to CR had
enhanced insulin-stimulated skeletal muscle IR tyrosine
kinase activity (data not shown) and increased IR -sub-
unit phosphorylation (Fig. 4A) and IRS-1 phosphorylation
(Fig. 4B). IRS-1 protein levels measured at the 5-, 20-, and
40-min time points did not differ from the value assessed
as the 0 time point. Although there was no signiﬁcant
difference in basal PI 3-kinase activity between the CR and
AL groups, insulin-stimulated PI 3-kinase activities were
signiﬁcantly higher when assessed at all time points post–
insulin stimulation in the CR group compared with those
in the AL group (Fig. 4C). Akt phosphorylation post–
insulin stimulation was also increased in skeletal muscle
with CR when compared with AL (Fig. 4D).
Genomic analysis. A total of 241 genes were identiﬁed as
signiﬁcantly differentially expressed with CR from 10,163
probes with a satisfactory quality of signals over all the
array slides. Among them, 179 genes were observed to be
downregulated and 62 genes upregulated. Using cluster
analysis, gene expression differed in 11 categories of
biological processes with 18% of genes involved in either
carbohydrate and lipid metabolism or signal transduction
(Fig. 5). Tables 1 and 2 list genes of interest in the muscle
that were either signiﬁcantly upregulated or downregu-
lated with CR for each biological process, respectively.
To conﬁrm the microarray ﬁndings, real-time qPCR
assays were conducted. Altogether, 27 genes were se-
lected from the microarray analysis to measure transcrip-
tion levels using RT-qPCR for which 22 were conﬁrmed to
have signiﬁcant changes in the CR compared with the AL
group (Table 3). Two genes, i.e., STAT3 and interleukin 6
signal transducer (IL6ST), did not show signiﬁcant
changes between AL and CR conditions as assessed with
real-time qPCR assays as opposed to the microarray
analysis, and expression of the type 3 iodothyronine
deiodinase (DIO3) gene with RT-qPCR did not agree with
the ﬁndings from the microarray. In addition, SIRT1 tran-
scriptional level in muscle from the CR monkeys was
signiﬁcantly increased compared with that from the AL
monkeys, as assessed by RT-qPCR assay.
From the list of genes conﬁrmed by RT-qPCR, LPL,
SGK1, SIRT1, and STAT3 were assessed for protein
abundance (Fig. 6). The protein abundance of LPL,
SGK1, and SIRT1 was signiﬁcantly increased in the CR
compared with the AL group (97, 57, and 35%, respec-
tively). In agreement with the PCR data, protein expres-
sion of STAT3 in the CR monkeys was not conﬁrmed by
Western blot analysis (Fig. 6). Because increased gene
expression of insulin signaling proteins (i.e., IRS-1,
IRS-2, and PI 3-kinase) was not noted, yet increased
protein content was observed, factors that regulate
protein content (i.e., degradation) were sought. The
majority of intracellular proteins are degraded by the
26S proteasome (32). Given the inhibitory effect of
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FIG. 3. Content of insulin receptor signaling proteins in the monkey
skeletal muscle obtained at basal state is demonstrated. IRS-1, IRS-2,
IR -subunit, PI 3-kinase (p85), and GLUT4 protein abundance in the
muscle were measured by Western blot analysis. Results were normal-
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change of AL at baseline. *P < 0.05, **P < 0.01, and ***P < 0.001 for
CR versus AL.
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radation (19,20), 20S proteasome activity was assayed in
the monkey muscle lysates. 20S proteasome activity in
muscle lysates was signiﬁcantly reduced in the CR
group compared with the AL group, although nonpro-
teasomal degradation measured in the presence of two
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FIG. 5. Percentage of 241 genes modulated by CR and sorted by biological process for which fold-change was >1.5 and P was <0.05 (n  5 per group).
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epoxomicin, was unchanged (Fig. 7A). Decreased 20S
proteasome activity with CR was associated with signiﬁ-
cantly decreased abundance of selected subunits of the
26S proteasome, including a subunit of the 20S catalytic
core (2i) and subunits of the 19S regulatory complex
base (S5A, which contains a ubiquitin binding site) and lid
(Rpn6 and Rpn12, two of eight non-ATPase subunits) (Fig.
7B and C), when compared with the AL group.
DISCUSSION
One of the most consistent physiological changes ob-
served with CR is the favorable effect on glucoregulation,
TABLE 1
Genes observed to be upregulated by CR
Accession Symbol Fold-change Gene name
Carbohydrate and lipid metabolism
NM_018677 ACSS2 1.53 Acyl-CoA synthetase short-chain family member 2
NM_001647 APOD 2.45 Apolipoprotein D
NM_000237 LPL 1.99 Lipoprotein lipase
NM_003706 PLA2G4C 2.73 Phospholipase A2, group IVC
NM_020422 LOC57146 2.60 Promethin
NM_022479 WBSCR17 1.69 Williams-Beuren syndrome chromosome region 17
Development (growth, cell cycle,
and apoptosis)
NM_022662 ANAPC1 RGPD1 1.52 Anaphase promoting complex subunit
NM_001798 CDK2 1.72 Cyclin-dependent kinase 2
NM_030588 DHX9 1.70 DEAH (Asp-Glu-Ala-His) box polypeptide 9
NM_004426 PHC1 1.56 Polyhomeotic-like 1
NM_001004125 TUSC1 1.55 Tumor suppressor candidate 1
NM_001077397 IRF2BP2 1.53 Interferon regulatory factor 2 binding protein 2
Other metabolism
NM_001003800 BICD2 1.51 Bicaudal D homolog 2 (Drosophila)
NM_003875 GMPS 1.63 Guanine monophosphate synthetase
NM_004813 PEX16 1.99 Peroxisomal biogenesis factor 16
NM_018663 PXMP2 1.88 Peroxisomal membrane protein 2, 22 kDa
Protein biosynthesis, metabolism,
and catabolism
NM_001010853 ACY1L2 1.93 Aminoacylase 1-like 2
NM_001414 EIF2B1 1.51 Eukaryotic translation initiation factor 2B, subunit 1
NM_176792 MRPL43 1.51 Mitochondrial ribosomal protein L43
NM_005401 PTPN14 1.64 Protein tyrosine phosphatase, non-receptor type 14
XM_114317 RPL22L1 1.90 Ribosomal protein L22-like 1
NM_005617 RPS14 2.42 Ribosomal protein S14
Signal transduction
NM_199327 SPRY1 1.51 Sprouty homolog 1, antagonist of FGF signaling
NM_000627 LTBP1 2.06 Latent transforming growth factor  binding protein 1
NM_001388 DRG2 1.56 Developmentally regulated GTP binding protein 2
NM_002184 IL6ST 1.62 Interleukin 6 signal transducer
NM_004887 CXCL14 2.88 Chemokine (C-X-C motif) ligand 14
NM_003150 STAT3 1.51 Signal transducer and activator of transcription 3
NM_021183 RAP2C 1.55 RAP2C, member of RAS oncogene family
Transcriptional regulation
NM_005316 GTF2H1 1.87 General transcription factor IIH
NM_006559 KHDRBS1 1.56 KH domain containing, RNA binding
NM_016199 LSM7 1.97 LSM7 homolog, U6 small nuclear RNA associated
NM_005120 MED12 1.56 Mediator of RNA polymerase II transcription
NM_002582 PARN 1.56 Poly(A)-speciﬁc ribonuclease
NM_006468 POLR3C 1.98 Polymerase (RNA) III polypeptide C (62 kD)
NM_006022 TSC22D1 1.69 TSC22 domain family, member 1
NM_004814 WDR57 1.51 WD repeat domain 57 (U5 snRNP speciﬁc)
NM_004773 ZNHIT3 1.63 Zinc ﬁnger, HIT type 3
Transport
NM_198098 AQP1 2.08 Aquaporin 1
NM_001650 AQP4 1.93 Aquaporin 4
NM_001752 CAT 1.73 Catalase
NM_000747 CHRNB1 1.54 Cholinergic receptor,  polypeptide 1 (muscle)
NM_003665 FCN3 2.21 Ficolin (collagen/ﬁbrinogen domain containing) 3
NM_001038618 NARF 1.51 Nuclear prelamin A recognition factor
NM_021977 SLC22A3 2.21 Solute carrier family 22, member 3
NM_016930 STX18 1.54 Syntaxin 18
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rhesus monkeys and rodents (1–3,15–17). Our data con-
ﬁrm that CR markedly improved insulin sensitivity in
cynomolgus monkeys when evaluated over a 4-year period
(14). In addition, we provide novel data regarding the
cellular mechanism of action of CR because the enhanced
TABLE 2
Genes downregulated by CR
Accession Symbol
Fold
change Gene name
Apoptosis
NM_023067 FOXL2 1.70 Forkhead box L2
NM_006054 RTN3 1.60 Reticulon 3
NM_182985 RNF36 1.60 Ring ﬁnger protein 36
Carbohydrate and lipid metabolism
NM_006212 PFKFB2 1.67 6-phosphofructo-2-kinase/fructose-2
NM_001607 ACAA1 2.40 Acetyl-coenzyme A acyltransferase 1
NM_017990 PDPR 1.50 Pyruvate dehydrogenase phosphatase regulatory
NM_014474 SMPDL3B 1.68 Sphingomyelin phosphodiesterase, acid-like 3B
Development (growth and cell cycle)
NM_004924 ACTN4 1.51 Actinin, 4
NM_003741 CHRD 1.69 Chordin
NM_001362 DIO3 2.42 Deiodinase, iodothyronine, type III
NR_002770 DIO3OS 1.72 Deiodinase, iodothyronine, type III opposite strand
NM_019612 IRGC 2.62 Immunity-related GTPase family, cinema
NM_181602 KRTAP6-1 1.80 Keratin associated protein 6-1
NM_005018 PDCD1 1.52 Programmed cell death 1
NM_152362 TNFAIP8L1 1.83 Tumor necrosis factor-–induced protein 8-like 1
Extracellular matrix
NM_152462 AMAC1 1.70 Acyl-malonyl condensing enzyme 1
NM_001625 AK2 2.61 Adenylate kinase 2
NM_001630 ANXA8 1.65 Annexin A8
NM_004933 CDH15 1.86 Cadherin 15, M-cadherin (myotubule)
NM_000632 ITGAM 1.89 Integrin, M
Protein biosynthesis, metabolism, and
catabolism
NM_007272 CTRC 1.52 Chymotrypsin C (caldecrin)
NM_031948 PRSS27 1.70 Protease, serine 27
NM_001001 RPL36AL 2.08 Ribosomal protein L36a-like
NM_171997 USP2 1.64 Ubiquitin speciﬁc peptidase 2
NM_017414 USP18 1.99 Ubiquitin speciﬁc peptidase 18
Signal transduction
NM_000054 AVPR2 1.92 Arginine vasopressin receptor 2
NM_005283 XCR1 1.86 Chemokine (C motif) receptor 1
NM_015722 DRD1IP 1.53 Dopamine receptor D1 interacting protein
NM_005301 GPR35 1.62 G protein–coupled receptor 35
NM_018485 GPR77 1.66 G protein–coupled receptor 77
NM_020400 GPR92 1.73 G protein–coupled receptor 92
NM_020988 GNAO1 1.56 Guanine nucleotide binding protein (G protein)
NM_005340 HINT1 2.74 Histidine triad nucleotide binding protein 1
NM_000894 LHB 1.52 Luteinizing hormone  polypeptide
NM_004160 PYY 2.15 Peptide YY
NM_004248 PRLHR 1.98 Prolactin releasing hormone receptor
Transcriptional regulation
NM_006161 NEUROG1 1.76 Neurogenin 1
NM_024019 NEUROG2 1.66 Neurogenin 2
NM_006231 POLE 1.53 Polymerase (DNA directed), epsilon
NM_138338 POLR3H 1.81 Polymerase (RNA) III (DNA directed) polypeptide H
NM_003317 TITF1 1.68 Thyroid transcription factor 1
NM_152600 ZNF579 1.62 Zinc ﬁnger protein 579
Transport
NM_006028 HTR3B 2.21 5-hydroxytryptamine (serotonin) receptor 3B
NM_138813 ATP8B3 2.66 ATPase, class I, type 8B, member 3
NM_013387 UCRC 2.73 Ubiquinol–cytochrome c reductase complex
NM_020443 NAV1 1.95 Neuron navigator 1
NM_020822 KCNT1 1.68 Potassium channel, subfamily T, member 1
NM_001038 SCNN1A 2.44 Sodium channel, nonvoltage-gated 1
NM_019025 SMOX 1.65 Spermine oxidase
NM_003374 VDAC1 1.56 Voltage-dependent anion channel 1
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opposed to AL, was associated with increased content of
proteins of the IR signal transduction pathway.
Enhanced insulin signaling was demonstrated in our
study with the ﬁnding of increases in IR kinase activities,
IR -subunit phosphorylation, and IRS-1–associated PI
3-kinase activities following insulin stimulation in the
muscle tissues in the CR group. The mechanism by which
insulin signaling is enhanced with CR has been suggested
to be secondary to an effect on transcriptional regulation.
For example, it has been reported that liver IR, IGF-1R,
and IRS-1 mRNA were greater in older rats subjected to 25
months of 40% CR than in AL-fed rats (33) and that CR also
had greater effect on the cardiac gene expression of IR,
IRS-1, IGF-1, IGF-1R, and GLUT4 compared with that in
age-matched controls (34). In contrast, studies reported
for primates subjected to CR do not support the observa-
tions in rodents as related to transcription. Kayo et al. (35)
evaluated skeletal muscle from rhesus monkeys subjected
to CR and reported increases in gene expression of
GLUT4, which agree with our data. Moreover, they also
reported increased gene expression of PI 3-kinase P110,
TABLE 3
Genes conﬁrmed by RT-qPCR in skeletal muscle
Accession Symbol Gene name
Microarray mean qPCR mean
Fold-change
(CR/AL) P
Fold-change
(CR/AL) P
Carbohydrate and lipid
metabolism
NM_000237 LPL Lipoprotein lipase 1.97 0.03 2.37 0.009
NM_006212 PFKFB2 6-phosphofructo-2-kinase/fructose-
2,6-biphosphatase 2
1.71 0.02 1.79 0.005
NM_003706 PLA2G4C Phospholipase A2, group IVC
(cytosolic, calcium-independent)
2.72 0.01 2.46 0.019
NR_002168 PPP1R2P3 Protein phosphatase 1, regulatory
subunit 2 pseudogene 3
2.5 0.03 1.42 0.006
Development (growth, apoptosis,
and cell cycle)
NM_000618 IGF1 Insulin-like growth factor 1 1.96 0.03 1.65 0.05
NM_000597 IGFBP2 Insulin-like growth factor binding
protein 2, 36 kDa
1.95 0.01 1.88 0.002
Genes with unknown process
NM_182972 IRF2BP2 Interferon regulatory factor 2
binding protein 2
1.50 0.01 1.60 0.002
Other process
NM_012238.3 SIRT1 Sirtuin 1 1.00 0.98 2.03 0.01
NM_001752 CAT Catalase 1.73 0.03 1.8 0.05
NM_001362 DIO3 Deiodinase, iodothyronine, type III 2.4 0.02 2.56 0.006
Protein metabolism
NM_005627 SGK1 Serum/glucocorticoid regulated
kinase 1
1.71 0.001 1.52 0.05
NM_017414 USP18 Ubiquitin speciﬁc peptidase 18 1.99 0.002 4.14 0.001
Signal transduction
NM_001388 DRG2 Developmentally regulated GTP
binding protein 2
1.6 0.04 2.93 0.05
NM_002184 IL6ST Interleukin 6 signal transducer 1.6 0.02 1.38 0.09
NM_005544 IRS1 Insulin receptor substrate 1 1.04 0.84 1.11 0.76
NM_003749 IRS2 Insulin receptor substrate 2 1.04 0.82 1.36 0.15
NM_000208 INSR Insulin receptor 1.36 0.06 1.81 0.01
NM_181504 PIK3R1 PI 3-kinase, regulatory subunit 1
(p85 )
1.19 0.47 1.25 0.1
NM_001042 SLC2A4 Glucose transporter 4 1.43 0.04 3.35 0.01
Transcriptional regulation
NM_001357 DHX9 DEAH (Asp-Glu-Ala-His) box
polypeptide 9
1.80 0.04 1.89 0.001
NM_023067 FOXL2 Forkhead box L2 1.7 0.01 1.59 0.05
NM_003150 STAT3 Signal transducer and activator of
transcription 3
1.5 0.01 1.36 0.28
Transportation
NM_198098 AQP1 Aquaporin 1 2.08 0.04 3.38 0.001
NM_182964 NAV2 Neuron navigator 2 1.6 0.02 2.17 0.03
NM_006054 RTN3 Reticulon 3 1.6 0.002 1.96 0.004
NM_013387 UCRC Ubiquinol–cytochrome c reductase
complex 7.2 kDa protein
2.7 0.004 2.17 0.005
Unknown genes
NM_020422 TMEM159 Transmembrane protein 159 2.70 0.04 1.44 0.03
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compared with the other reported studies in that we
evaluated a different primate species (i.e., cynomolgus vs.
rhesus monkeys), a different dietary content (i.e., athero-
genic diet vs. chow), and a later start date for initiation of
CR (14–18,35).
Given our observations, the major question would be
the mechanism by which insulin signaling protein content
in muscle is increased without a signiﬁcant effect on
transcriptional regulation. Ambient protein levels are de-
termined by the coordinated interplay of metabolic pro-
cesses that involve transcription, mRNA translation, and
degradation (36). Transcription and degradation mecha-
nisms have received signiﬁcant attention, and regulation at
the level of mRNA translation as an independent mecha-
nism is suggested when mRNA and protein levels do not
correlate (36). It is also reported that the content of IRS-1
and IRS-2 is inﬂuenced by many factors, including growth
factors and cytokines, and conditions associated with
insulin resistance have been reported to exhibit increases
in whole-body protein degradation (37,38). Studies using
cell lines or isolated primary cells chronically exposed to
insulin have revealed that the reduced level of IRS-1
protein is due to enhanced degradation (39). Other studies
have demonstrated that a major effect of insulin is regula-
tion of protein degradation mediated by the proteasome
(19,20). Based on these reports and from our microarray
ﬁndings, the next logical step was to evaluate whether the
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lated by CR.
Ubiquitin-dependent proteolysis plays an important role
in regulating fundamental biological functions, including
cell division and cellular differentiation. The proteasome
degradation system is composed of two distinct and
successive steps: ubiquitin conjugation and proteasome
degradation (40). Ubiquitin is ﬁrst activated by a single
ubiquitin-activating enzyme, E1. Following activation, one
of several E2 enzymes (ubiquitin-conjugating proteins)
transfers ubiquitin from E1 to a member of the ubiquitin-
protein ligase family, E3, to which the substrate protein is
speciﬁcally bound. E3 catalyzes the last step in the conju-
gation process, covalent attachment of ubiquitin to the
substrate (41). Ubiquitin-tagged proteins are then recog-
nized and degraded by the 26S proteasome complex,
which consists of the 20S catalytic core complex capped
on one or both ends by 19S regulatory complexes (32). In
support of the hypothesis that CR may modulate the
ubiquitin-proteasome system, transcriptional levels of
ubiquitin-speciﬁc peptidase 2 and 18 (USP2 and USP18)
were reduced. Moreover, skeletal muscle from animals
randomized to CR had decreased 20S proteasome activity
and greatly reduced protein abundance of selected protea-
some subunits. Collectively, our data support the hypoth-
esis that CR enhances the insulin signaling cascade, and
one of the contributing mechanisms may be secondary to
modulating the ubiquitin-proteasome system in skeletal
muscle.
There were other genes of interest that were modulated
with CR including those involved in lipid metabolism, e.g.,
LPL and related enzyme transcriptional levels (Tables
1–3). In addition, we observed signiﬁcantly increased
SIRT1 protein abundance and gene expression with CR in
primates. This result appears to be consistent with data
found in rodent studies (11,42), but other investigators
suggest that the regulation of SIRT1 activity during CR
may be tissue speciﬁc (43). Thus, the relationship between
SIRT1 and insulin signaling in CR animals needs to be
further studied.
Our data demonstrating that insulin signaling proteins
are increased in muscle with CR appear to be in contrast
to many published studies. For example, Gazdag et al. (18)
evaluated CR in rhesus monkeys and reported only that
the content of IRS-1 approached signiﬁcance (P 	 0.051).
Friedman et al. (44) reported no change in GLUT4 protein
in skeletal muscle but observed a signiﬁcant improvement
in insulin sensitivity in obese human subjects after an
average weight loss of 36%. Kim et al. (45) reported
improvement in insulin sensitivity with enhanced insulin-
stimulated receptor and IRS-1 tyrosine phosphorylation
without change in protein content in muscle. Previously,
we reported that there was no change in GLUT4 levels for
heart or diaphragm muscle between AL or CR animals
despite increase in insulin sensitivity (22). Thus, it is
important to note that an increase in insulin signaling
proteins or GLUT4 abundance does not appear to be
essential for increased insulin sensitivity with reduction in
caloric intake. Taken together, the mechanism by which
CR has its effects on insulin action in cynomolgus mon-
keys may be different from those reported in other species
that demonstrate improved insulin action with CR (i.e.,
humans, rhesus monkeys, rats, and mice) (1–3,13–18,42).
It is not known at this time whether the differences are
related to the species, composition of diet, age at CR
initiation, length of CR intervention, or other factors.
In summary, our data demonstrate that CR enhances
insulin sensitivity and skeletal muscle content of insulin
signaling proteins in cynomolgus monkeys. Because am-
bient protein levels are determined by transcription,
mRNA translation, and degradation, any of these pro-
cesses could have contributed to the observations. How-
ever, the data do support the ﬁnding that a contributing
cellular mechanism by which CR enhances insulin action
in vivo may be secondary to modulation of protein degra-
dation via the ubiquitin-proteasome system. The mecha-
nism for the speciﬁcity for the sparing of degradation of
insulin signaling proteins, but not most proteins, remains
unexplained and will need to be conﬁrmed with more
precise mechanistic studies.
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